All News

Ramucirumab improved overall survival and progression-free survival in patients with advanced hepatocellular carcinoma who have a high alpha-fetoprotein.

Officials with the FDA have accepted a new drug application (NDA) for Alkermes once-daily, oral, investigative major depressive disorder (MDD) therapy, ALKS 5461, intended for use in patients with an inadequate response to standard antidepressant treatment.

Although the risk of neurocognitive issues is common in survivors of childhood lymphoblastic leukemia (ALL), a new study suggests that the risk may actually begin before treatment.

Top news of the day from across the health care landscape.

Top news of the day from across the health care landscape.

The FDA recently released a new app to highlight newly approved drugs, and to give users some quick information on medications. The app, more or less, is a lighter version of their Drugs@FDA website.

The number of Americans concerned about opioid addiction rises 10% in just 2 years.

A recent study raises the question of whether this unusual idea could be widely adopted.

It is important that pharmacists know the real deal about this mainstay of a healthy diet.

Life is like a jungle gym, it is filled with twists and turns, with no clear path. How pharmacists adjust to those twist and turns is a test of resilience, and sheer will.

The odorless, bitter, yellow agent known as picric acid was once used in burn relief and surgical procedures.

Smart Inhalers have been around for awhile, but have been consigned to use primarily in clinical trials. One company is bringing them to the OTC market.

Pharmacists often encounter patients with Heparin-induced Thrombocytopenia (HIT) in health care settings. Here are some useful information in regards to HIT.

Upadacitinib, an oral agent designed to selectively inhibit JAK1, is being studied as a once-daily therapy in rheumatoid arthritis.

For its upcoming Directions in Pharmacy® conference in Nashville, Tennessee, Pharmacy Times Continuing EducationTM is partnering with Lilly USA, LLC to present “An Insulin Monotherapy Option for Patients on High Doses of Insulin.”

Top news of the day from across the health care landscape.

Top news of the day from across the health care landscape.